


bs-1035R**[Primary Antibody]****Cd86 | B7-2 Rabbit pAb****Bioss**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

DATASHEET**Host:** Rabbit**Isotype:** IgG**Clonality:** Polyclonal**GeneID:** 942**SWISS:** P42081**Target:** Cd86 | B7-2**Immunogen:** Recombinant human CD86 protein: 24-239/329. < Extracellular >**Purification:** affinity purified by Protein A**Concentration:** 1mg/ml**Storage:** 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.**Background:** This gene encodes a type I membrane protein that is a member of the immunoglobulin superfamily. This protein is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of this protein with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. Alternative splicing results in several transcript variants encoding different isoforms.[provided by RefSeq, May 2011].**Applications:** WB (1:500-2000)**IHC-P** (1:100-500)**IHC-F** (1:100-500)**IF** (1:100-500)**Flow-Cyt** (1µg/Test)**ICC/IF** (1:50-200)**Reactivity:** Human, Mouse, Rat**Predicted MW.:** 31 kDa**Observed MW.:** 68 kDa**Subcellular Location:** Cell membrane**VALIDATION IMAGES**


25 µg total protein per lane of various lysates (see on figure) probed with CD86 polyclonal antibody, unconjugated (bs-1035R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.



Tissue/cell: Human esophageal carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Incubation: Anti-CD86/B7-2 Polyclonal Antibody, Unconjugated(bs-1035R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining



4% Paraformaldehyde-fixed Daudi (H) cell; Antibody incubation with (CD86) polyclonal Antibody, unconjugated (bs-1035R) 1:100, 90 min at 37°C; followed by conjugated Goat Anti-Rabbit IgG antibody (green, bs-40295G-FITC) at 37°C for 90 min, DAPI (blue, C02-04002) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.



The MJ (H) cells were incubated in 5%BSA to block non-specific protein-protein interactions (30 min at r.t.), followed by secondary antibody incubation for 40 min at room temperature. Primary Antibody (green): Rabbit Anti-CD86

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

antibody (bs-1035R): 1 μ g/ 10^6 cells; Isotype
Control (orange): Rabbit IgG (bs-0295P). Blank
control (black): PBS. Acquisition of 20,000 events
was performed.

— SELECTED CITATIONS —

- **[IF=22]** Fujun Yang. et al. Molecularly tailoring an oxygen-carrying binary nanomodulator for integrated hypoxia/immunosuppression relief and hypersensitive immunogenic chemotherapy of triple-negative breast cancer. *MATER TODAY*. 2026 May;94:103261 FC ;Mouse. 10.1016/j.mattod.2026.103261
- **[IF=21.3]** Liu Haoran. et al. A Bioflexible Janus Dressing with Unidirectional Drainage for Dynamic pH Monitoring, Exudate Management, and Immune Modulation in Diabetic Wound Healing. *ADV FIBER MATER*. 2026 Mar;;1-15 IHC ;Rat. 10.1007/s42765-025-00661-3
- **[IF=20.722]** Meng Lin. et al. CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy. *Nano Today*. 2022 Feb;42:101359 IF ;Mouse. 10.1016/j.nantod.2021.101359
- **[IF=19]** Luyao Feng. et al. A Versatile Approach to Synergistically Combine Physical Barriers and Bioactive Agents for Intrauterine Adhesion Prevention. *ADV FUNCT MATER*. 2025 Oct;;e14793 IF ;Mouse. 10.1002/adfm.202514793
- **[IF=19]** Xuezhe Liu. et al. Transient Hyperoxia-Generating Interface Coupled with Mg²⁺ Delivery Reprograms Osteoimmune Microenvironment for Enhancing Osseointegration. *ADV FUNCT MATER*. 2025 Sep;;e14674 IF ;Mouse. 10.1002/adfm.202514674